949 related articles for article (PubMed ID: 17981916)
1. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients.
Gerloni V; Pontikaki I; Gattinara M; Fantini F
Ann Rheum Dis; 2008 Aug; 67(8):1145-52. PubMed ID: 17981916
[TBL] [Abstract][Full Text] [Related]
2. [Side effects of anti-TNFalpha therapy in juvenile idiopathic arthritis].
Pontikaki I; Gerloni V; Gattinara M; Luriati A; Salmaso A; De Marco G; Teruzzi B; Valcamonica E; Fantini F
Reumatismo; 2006; 58(1):31-8. PubMed ID: 16639486
[TBL] [Abstract][Full Text] [Related]
3. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis.
Tynjälä P; Vähäsalo P; Honkanen V; Lahdenne P
Ann Rheum Dis; 2009 Apr; 68(4):552-7. PubMed ID: 18467515
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry.
Horneff G; De Bock F; Foeldvari I; Girschick HJ; Michels H; Moebius D; Schmeling H;
Ann Rheum Dis; 2009 Apr; 68(4):519-25. PubMed ID: 18413440
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register.
Prince FH; Twilt M; ten Cate R; van Rossum MA; Armbrust W; Hoppenreijs EP; van Santen-Hoeufft M; Koopman-Keemink Y; Wulffraat NM; van Suijlekom-Smit LW
Ann Rheum Dis; 2009 May; 68(5):635-41. PubMed ID: 18413443
[TBL] [Abstract][Full Text] [Related]
6. [Indications and adverse events with the use of anti-TNFalpha agents in pediatric rheumatology: experience of a single center].
de Oliveira SK; de Almeida RG; Fonseca AR; Rodrigues MC; Sztajnbok F; Diniz C
Acta Reumatol Port; 2007; 32(2):139-50. PubMed ID: 17572652
[TBL] [Abstract][Full Text] [Related]
7. Experiences with tumour necrosis factor-{alpha} inhibitors in patients with juvenile idiopathic arthritis: Hungarian data from the National Institute of Rheumatology and Physiotherapy Registry.
Sevcic K; Orban I; Brodszky V; Bazso A; Balogh Z; Poor G; Kiss E
Rheumatology (Oxford); 2011 Jul; 50(7):1337-40. PubMed ID: 21372001
[TBL] [Abstract][Full Text] [Related]
8. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type.
Quartier P; Taupin P; Bourdeaut F; Lemelle I; Pillet P; Bost M; Sibilia J; Koné-Paut I; Gandon-Laloum S; LeBideau M; Bader-Meunier B; Mouy R; Debré M; Landais P; Prieur AM
Arthritis Rheum; 2003 Apr; 48(4):1093-101. PubMed ID: 12687553
[TBL] [Abstract][Full Text] [Related]
10. Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies.
Jonsdottir T; Forslid J; van Vollenhoven A; Harju A; Brannemark S; Klareskog L; van Vollenhoven RF
Ann Rheum Dis; 2004 Sep; 63(9):1075-8. PubMed ID: 15066863
[TBL] [Abstract][Full Text] [Related]
11. [Clinical experience with TNF-alpha inhibitors in rheumatoid arthritis].
Wallenius M; Rødevand E; Skomsvoll JF
Tidsskr Nor Laegeforen; 2005 Jun; 125(12):1664-6. PubMed ID: 15976836
[TBL] [Abstract][Full Text] [Related]
12. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis.
Tynjälä P; Lindahl P; Honkanen V; Lahdenne P; Kotaniemi K
Ann Rheum Dis; 2007 Apr; 66(4):548-50. PubMed ID: 17068061
[TBL] [Abstract][Full Text] [Related]
13. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.
Gómez-Reino JJ; Carmona L; Valverde VR; Mola EM; Montero MD;
Arthritis Rheum; 2003 Aug; 48(8):2122-7. PubMed ID: 12905464
[TBL] [Abstract][Full Text] [Related]
14. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis.
Saurenmann RK; Levin AV; Rose JB; Parker S; Rabinovitch T; Tyrrell PN; Feldman BM; Laxer RM; Schneider R; Silverman ED
Rheumatology (Oxford); 2006 Aug; 45(8):982-9. PubMed ID: 16461435
[TBL] [Abstract][Full Text] [Related]
15. Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases.
Fautrel B; Sibilia J; Mariette X; Combe B;
Ann Rheum Dis; 2005 Feb; 64(2):262-6. PubMed ID: 15184196
[TBL] [Abstract][Full Text] [Related]
16. Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects.
Iannone F; Trotta F; Montecucco C; Giacomelli R; Galeazzi M; Matucci-Cerinic M; Ferri C; Cutolo M; Maria Bambara L; Triolo G; Ferraccioli G; Valentini G; Lapadula G;
Ann Rheum Dis; 2007 Feb; 66(2):249-52. PubMed ID: 16837489
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of once weekly etanercept 0.8 mg/kg in a multicentre 12 week trial in active polyarticular course juvenile idiopathic arthritis.
Horneff G; Ebert A; Fitter S; Minden K; Foeldvari I; Kümmerle-Deschner J; Thon A; Girschick HJ; Weller F; Huppertz HI
Rheumatology (Oxford); 2009 Aug; 48(8):916-9. PubMed ID: 19483091
[TBL] [Abstract][Full Text] [Related]
18. Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNFalpha agents.
Saurenmann RK; Levin AV; Feldman BM; Laxer RM; Schneider R; Silverman ED
J Pediatr; 2006 Dec; 149(6):833-6. PubMed ID: 17137902
[TBL] [Abstract][Full Text] [Related]
19. Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis--data from the dutch arthritis and biologicals in children register, 1999-2010.
Otten MH; Prince FH; Twilt M; Ten Cate R; Armbrust W; Hoppenreijs EP; Koopman-Keemink Y; Wulffraat NM; Gorter SL; Dolman KM; Swart JF; van den Berg JM; van Rossum MA; van Suijlekom-Smit LW
J Rheumatol; 2011 Oct; 38(10):2258-63. PubMed ID: 21844151
[TBL] [Abstract][Full Text] [Related]
20. A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti-tumor necrosis factor alpha agents.
Lurati A; Pontikaki I; Teruzzi B; Desiati F; Gerloni V; Gattinara M; Cimaz R; Fantini F
Arthritis Rheum; 2006 May; 54(5):1602-7. PubMed ID: 16646003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
